| 241.06 -2.04 (-0.84%) | 10-21 13:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 285.75 | 1-year : | 333.75 |
| Resists | First : | 244.64 | Second : | 285.75 |
| Pivot price | 228.77 |
|||
| Supports | First : | 226.07 | Second : | 214.58 |
| MAs | MA(5) : | 237 |
MA(20) : | 228.36 |
| MA(100) : | 211.98 |
MA(250) : | 192.72 |
|
| MACD | MACD : | 4.9 |
Signal : | 3.6 |
| %K %D | K(14,3) : | 83.4 |
D(3) : | 77.4 |
| RSI | RSI(14): 66.3  |
|||
| 52-week | High : | 244.64 | Low : | 138 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BIIB ] has closed below upper band by 9.4%. Bollinger Bands are 55.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 244.95 - 245.86 | 245.86 - 246.59 |
| Low: | 233.81 - 234.95 | 234.95 - 235.85 |
| Close: | 241.37 - 243.15 | 243.15 - 244.58 |
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Wed, 21 Oct 2026
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm - Seeking Alpha
Wed, 21 Oct 2026
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Tue, 20 Oct 2026
A Look at Biogen Inc (BIIB) After 4.1% Gain -- GF Value $202.16 vs Price $243.10 - GuruFocus
Tue, 20 Oct 2026
symbol__ Stock Quote Price and Forecast - CNN
Mon, 19 Oct 2026
Urine protein fell over 76 weeks; Biogen will present the kidney data. - Stock Titan
Fri, 16 Oct 2026
Biogen (BIIB) On Lupus Trial Results Looks Fully Valued Or Still Worth Buying - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 148 (M) |
| Shares Float | 147 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 99.5 (%) |
| Shares Short | 5,970 (K) |
| Shares Short P.Month | 5,730 (K) |
| EPS | 5.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 127.61 |
| Profit Margin | 8.3 % |
| Operating Margin | 25 % |
| Return on Assets (ttm) | 5.2 % |
| Return on Equity (ttm) | 4.5 % |
| Qtrly Rev. Growth | 3.4 % |
| Gross Profit (p.s.) | 53.13 |
| Sales Per Share | 67.88 |
| EBITDA (p.s.) | 22.74 |
| Qtrly Earnings Growth | -84.9 % |
| Operating Cash Flow | 2,880 (M) |
| Levered Free Cash Flow | 1,270 (M) |
| PE Ratio | 42.71 |
| PEG Ratio | 2.2 |
| Price to Book value | 1.88 |
| Price to Sales | 3.54 |
| Price to Cash Flow | 12.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|